For some men with prostate cancer, radical treatment such as surgery or radiotherapy is the most suitable option. However, for others, it is preferable just to monitor the cancer regularly for signs that it may be getting worse or progressing. This treatment option is called active surveillance.
Doctors will often recommend active surveillance for patients with cancers that don’t need aggressive treatment when they are found. Some cancers will never progress beyond the stage they are when first diagnosed, so active surveillance can mean that unnecessary radical treatment is avoided. However, others will become more serious over time, and will eventually need further treatment.
PROVENT aims to see whether Aspirin and/or Vitamin D3 can help to stop prostate cancer progressing to a more serious condition in patients on active surveillance.
The main objective of the PROVENT feasibility study is to find out whether the men we would like to take part in the study, actually want to take part. The feasibility study will also help us work out how long it will take for enough men to join, whether the study is practical and if we need to change anything about how the trial is organised.
We are currently inviting men whose prostate cancer is managed by active surveillance to join the study. We hope to recruit 102 men from 6 UK trial centres within 12 months. If our findings are positive, we hope to expand PROVENT to include over 1000 men across many more centres nationwide.